IDO1 Human shRNA Plasmid Kit (Locus ID 3620)

SKU
TL312147
IDO1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
  $1,013.00
In Stock*
Specifications
Specifications
Product Data
Locus ID 3620
Synonyms IDO; IDO-1; INDO
Vector pGFP-C-shLenti
E. coli Selection Chloramphenicol (34 ug/ml)
Mammalian Cell Selection Puromycin
Format Lentiviral plasmids
Components IDO1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 3620). 5µg purified plasmid DNA per construct
29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq NM_002164, NM_002164.1, NM_002164.2, NM_002164.3, NM_002164.4, NM_002164.5, BC027882, BC027882.1, NM_002164.6
UniProt ID P14902
Summary This gene encodes indoleamine 2,3-dioxygenase (IDO) - a heme enzyme that catalyzes the first and rate-limiting step in tryptophan catabolism to N-formyl-kynurenine. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme is thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity. Through its expression in dendritic cells, monocytes, and macrophages this enzyme modulates T-cell behavior by its peri-cellular catabolization of the essential amino acid tryptophan.provided by RefSeq, Feb 2011
shRNA Design These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Storage Store at -20°C
Shipping Ambient
Reviews
 
 
 
 
 

Be the first to review this product

Please note:
Only reviews with images are eligible for a $20/20€ Amazon gift card.
Reviews without images are eligible for a $10/10€ Amazon gift card.
For more details about the terms and conditions, please visit the promotion page.

Review image
Documents
Resources

file-alt Citations

Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer
Wu, Spector, Theodoropoulos et al
Cancer Metab (2023) 11 (1), 7 DOI: 10.1186/s40170-023-00307-1
Cited by 74
AI Summary: OriGene’s pGFP-C-shLenti plasmid expressing shIDO1 (NM_002164) and the non-effective 29-mer scrambled shRNA control (cat no. TL312147) were used to stably knock down IDO1 in cisplatin-resistant NSCLC cells, enabling the study of IDO1’s role in tumor immune evasion and resistance mechanisms.
Snippet: ting of Ido1 For stable knockdown (shRNA) of IDO1, CR (ALC) cells were transfected with 1 μg of pGFP-C-shLenti plasmid expressing shIDO1 (NM_002164) or non-effective 29-mer scrambled shRNA control (Origene, cat no. TL312147) using lipofectamine 3000 (Thermo Fisher, Waltham, MA, USA) as transfection reagent in Opti-MEM medium. After 24 h, transfection medium Opti-MEM was exchanged to RPMI1640 co;For stable knockdown (shRNA) of IDO1, CR (ALC) cells were transfected with 1 μg of pGFP-C-shLenti plasmid expressing shIDO1 (NM_002164) or non-effective 29-mer scrambled shRNA control (Origene, cat no. TL312147) using lipofectamine 3000 (Thermo Fisher, Waltham, MA, USA) as transfection reagent in Opti-MEM medium. …
FigureFigureFigure
Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer
Wu, Spector, Theodoropoulos et al
Research Square (2022)
Cited by 1
Snippet: … We have Save;For stable knockdown (shRNA) of IDO1, CR (ALC) cells were transfected with 1µg of pGFP-C-shLenti plasmid expressing shIDO1 (NM_002164) or non-effective 29-mer scrambled shRNA control (Origene, cat no. TL312147) using lipofectamine 3000 (Thermo Fisher, Waltham, MA;USA) as transfection reagent in Opti-MEM medium. …
Targeting the kynurenine pathway for the treatment of cisplatin resistant lung cancer
Nguyen, Theodoropoulos, Li et al
Mol. Cancer Res. (2019) 18 (1), 105-117 DOI: 10.1158/1541-7786.MCR-19-0239
AI Summary: In this study, OriGene's pGFP-C-shLenti plasmid expressing shIDO1 (NM_002164) and scrambled control were used to achieve stable knockdown of IDO1 in lung cancer cells, enabling the investigation of IDO1's role in cisplatin resistance.
Snippet: 8 For stable knockdown (shRNA) of IDO1, ALC cells were transfected with 1µg of pGFP-C- shLenti plasmid (Origene) expressing shIDO1 (NM_002164) or scrambled control using lipofectamine 2000 (Thermo Fisher) transfection reagent (see Supplemental Method);- 8 For stable knockdown (shRNA) of IDO1, ALC cells were transfected with 1µg of pGFP-C- shLenti plasmid (Origene) expressing shIDO1 (NM_002164) or scrambled control using lipofectamine 2000 (Thermo Fisher) transfection reagent (see Supplemental Method)
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells
Liu, Liang, Yin et al
Nat Commun (2017) 8, 15207 DOI: 10.1038/ncomms15207
AI Summary: OriGene products—including pGFP-C-shLenti-shIDO1, pLenti-C-Myc-DDK-IDO1, pGFP-C-shLenti-shAHR, pCMV6-AHR, and pGFP-C-shLenti-shSTAT1—were used to manipulate the expression of key genes (IDO1, AHR, STAT1) to investigate their roles in IFN-γ-induced dormancy of tumor-repopulating cells.
Snippet: pGFP-C-shLenti-shIDO1, pLenti-C-Myc-DDK-IDO1, pGFP-C-shLenti-shAHR, pCMV6-AHR and pGFP-C-shLenti-shSTAT1 were purchased from Origene (MD, USA)
FigureFigureFigure
Showing 1-4 of 4 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Related Products